Sign in
Taking peopleNo phase

Building a score to predict clots and bleeding in people with cancer-associated thrombosis

Develops a risk score for repeat clots and bleeding in cancer-associated thrombosis.

Key facts

Who runs it
Ottawa Hospital Research Institute
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
Status
Recruiting
People taking part
1,000 people, planned
Started
3 Dec 2024
Expected to end
Dec 2027
Type of study
Observational
Record updated
25 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active cancer who have a blood clot in a vein and will take blood thinners for at least 6 months.

Age
18 years and older
Sex
All
Disease stage
Active cancer of any type, with a confirmed blood clot: deep vein clot in an arm or leg (DVT), lung clot (PE), clot in belly veins (splanchnic vein thrombosis) or in brain veins (cerebral sinus vein thrombosis). Expected life span over 6 months.
Earlier treatment
Planned treatment of the clot for at least 6 months with blood thinners (anticoagulants) by injection or by mouth, at full treatment dose.

Main reasons for not taking part

  • Clots in unusual places: gonadal, ovarian or retinal veins
  • Clot only in a surface vein (superficial vein thrombosis)
  • Refusing consent after more than 72 hrs on blood thinners
  • Younger than 18 years

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
  • Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing
  • Estimated life expectancy > 6 months
  • Willingness to give an informed consent
  • Age ≥ 18 years

Who cannot take part

  • Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
  • Superficial vein thrombosis
  • Age < 18 years old
  • Refusal of informed consent > 72 hrs of anticoagulants

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
Plain-language title
Building a score to predict clots and bleeding in people with cancer-associated thrombosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
25 March 2025